Striatonigral Tachykinin Biosynthesis I. Effect of the Dopamine Antagonist Haloperidol

  • M. J. Bannon
  • J.-M. Lee
  • P. Giraud
  • A. C. Young
  • H.-U. Affolter
  • T. I. Bonner
Conference paper


The prominent substance P (SP) projection from the striatum to the substantia nigra is thought to play an important role in the regulation of basal ganglia function and the response to dopaminergic and other pharmacological agents. However, the physiological and pharmacological significance of this striatonigral tachykinin system has been difficult to assess, since no useful measures of SP turnover have been available. Previous studies have shown that the repeated administration of dopamine (DA) antagonist (antipsychotic) drugs decreases the concentration of SP in the substantia nigra [1–5], although the relationship between SP concentration and SP turnover remains obscure. It has recently been demonstrated [6,7] that two mRNAs derived from one preprotachykinin (PPT) gene by alternate RNA splicing encode for either SP alone (αPPT mRNA) or both SP and the newly discovered tachykinin [8,9] substance K (SK) (βPPT mRNA). Thus, the biosynthes is of these two tachykinins could be differentially regulated in response to DA antagonists or other stimuli. In the present experiments, striatonigral SP and SK immunoreactivities were characterized using specific radioimmunoassays (RIAs) coupled to high performance liquid chromatography (HPLC). The acute and chronic effects of the antipsychotic drug haloperidol on the levels of striatonigral PPT mRNA (as well as SP and SK peptide levels) in single rat brain striata were quantitated as a dynamic index of tachykinin turnover.


High Performance Liquid Chromatography Substantia Nigra Haloperidol Treatment Basal Ganglion Function Nigral Substance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hong JS, Yang H-YT, Costa E (1978) Substance P content of substantia nigra after chronic treatment with antischizophrenic drugs. Neuropharmacol 17: 83–85CrossRefGoogle Scholar
  2. 2.
    Hanson GR, Alphs L, Pradhan S, Lovenberg W (1981) Response of striatonigral substance P systems to a dopamine receptor agonist and antagonist. Neurophramacol 20: 541–548CrossRefGoogle Scholar
  3. 3.
    LeDouarin C, Oblin A, Fage D, Scatton B (1983) Influence of lithium on biochemical manifestation of striatal dopamine target cell super sensitivity induced by prolonged haloperidol treatment. Eur J Pharmacol 93: 55–62CrossRefGoogle Scholar
  4. 4.
    Oblin A, Zivkovic B, Bartholini G (1984) Involvement of the D-2dopamine receptor in the neuroleptic-induced decrease in nigral substance P. Eur J Pharmacol 105: 175–177PubMedCrossRefGoogle Scholar
  5. 5.
    Bannon MJ, Lee J-M, Giraud P, Young A, Affolter H-U, Bonner TI (1986) Dopamine antagonist haloperidol decreases substance P, substance K, and preprotachykinin mRNAs in rat striatonigral neurons. J BioI Chem 261: 6640–6642Google Scholar
  6. 6.
    Nawa H, Hirose T, Takashima H, Inayama S, Nakanishi S (1983) Nucleotide sequences of cloned cDNAs for two types of bovine brain substance P precursor. Nature 306: 32–34PubMedCrossRefGoogle Scholar
  7. 7.
    Nawa H, Kotari H, Nakanishi S (1984) Tissue specific generation of two preprotachykinin mRNAs from one gene by alternate RNA splicing. Nature 312: 729–734PubMedCrossRefGoogle Scholar
  8. 8.
    Maggio JE, Sandberg BEB, Bradley CV, Iversen LL, Santikarn S, Williams DH, Hunter JC, Hanley MR (1983) Substance K: A novel tachykinin in mammalian spinal cord. Irish J Med Sci 152 (Suppl 1) 20–21Google Scholar
  9. 9.
    Kimura S, Okada M, Sugita Y, Kanazawa I, Munekata E (1983) Novel neuropeptides, neurokinin α. and β, isolated from porcine spinal cord. Proc Jpn Acad Ser B 59: 101–104CrossRefGoogle Scholar
  10. 10.
    Deutch AY, Tam S-Y, Roth RH (1985) Footshock and conditioned stress increase DOPAC in the ventral tegmental area but not the substantia nigra. Brain Res 333: 143–146PubMedCrossRefGoogle Scholar
  11. 11.
    Lee JM, McLean S, Maggio JE, Zamir N, Roth RH, Eskay RL, Bannon MJ (1986) The localization and characterization of substance P and substance K in striatonigral neurons. Brain Res 371: 152–154PubMedCrossRefGoogle Scholar
  12. 12.
    Kangawa K, Minamino N, Fukada A, Matsuo H (1980) Neuromedin K: a novel mammalian tachykinin identified in porcine spinal cord. Biochem Biophys Res Commun 114: 533–540CrossRefGoogle Scholar
  13. 13.
    Bannon MJ, Goedert M (1984) Changes in substance P concentrations after synthesis inhibition provide an index of substance P utilization. Brain Res 301: 184–186PubMedCrossRefGoogle Scholar
  14. 14.
    Bunney BS (1983) The electrophysiological pharmacology of midbrain dopaminergic systems. In: Horn AS, Korf J, Westerink BHC (eds) The Neurobiology of Dopamine. New York: Academic PressGoogle Scholar
  15. 15.
    Hong JS, Yoshikawa K, Kanamatsu T, Sabol SL (1985) Modulation of striatal enkephalinergic neurons by antipsychot ic drugs. Fed Proc 44: 2535–2539PubMedGoogle Scholar
  16. 16.
    Tang F, Costa E, Schwartz JP (1983) Increase of proenkephalin mRNA and enkephalin condition of rat striatum after daily injection of haloperidol for 2 to 3 weeks. Proc Natl Acad Sci USA 30: 3841–3844CrossRefGoogle Scholar
  17. 17.
    Blanc D, Cupo A, Castanas E, Bourhim N, Giraud P, Bannon MJ, Eiden LE (1985) Influence of acute subchronic and chronic tr,eatment with neuroleptic (haloperidol) on enkephalins and their precursors in the striatum of rat brain. Neuropeptides 5: 567–570PubMedCrossRefGoogle Scholar
  18. 18.
    Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Gillman SG, Goodman LS, RaIl TW, Murad F (eds) The Pharmacological Basis of Therapeutics. New York: Macmillan Publishing CoGoogle Scholar
  19. 19.
    Mauborgne A, Javoy-Agid F, Legrand JD, Agid Y, Cessalin F (1983) Decrease of substance P-like immunoreactivity in the substantia nigra and pall idum of parkinsonian brains. Brain Res 268: 167–170PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1987

Authors and Affiliations

  • M. J. Bannon
    • 1
  • J.-M. Lee
    • 1
  • P. Giraud
    • 2
  • A. C. Young
    • 2
  • H.-U. Affolter
    • 2
  • T. I. Bonner
    • 2
  1. 1.Department of Psychiatry and PharmacologyYale University School of Medicine and the Abraham Ribicoff Research Facilities, Connecticut Mental Health CenterNew HavenUSA
  2. 2.Laboratory of Cell BiologyNational Institute of Mental HealthBethesdaUSA

Personalised recommendations